Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression
Ha-Young Park, In-Jae Oh, Bo Gun Kho, Tae-Ok Kim, Hong-Joon Shin, Cheol Kyu Park, Yong-Soo Kwon, Yu-Il Kim, Sung-Chul Lim, Young-Chul Kim, Yoo-Duk Choi
Tuberc Respir Dis. 2019;82(3):227-233.   Published online 2019 Feb 28     DOI: https://doi.org/10.4046/trd.2018.0070
Citations to this article as recorded by Crossref logo
The detection of PD‐L1 expression on liquid‐based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid‐based cytology and cell block samples
Haiyue Ma, Jia Jia, Zihan Sun, Xiaoyue Xiao, Shuo Liang, Linlin Zhao, Zhihui Zhang
Diagnostic Cytopathology.2024; 52(5): 235.     CrossRef
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Associ
Lynette M. Sholl, Mark Awad, Upal Basu Roy, Mary Beth Beasley, Richard Walter Cartun, David M. Hwang, Gregory Kalemkerian, Fernando Lopez-Rios, Mari Mino-Kenudson, Ajit Paintal, Kearin Reid, Lauren Ritterhouse, Lesley A. Souter, Paul E. Swanson, Christina
Archives of Pathology & Laboratory Medicine.2024; 148(7): 757.     CrossRef
Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer
Da Hyun Kang, Chang-Min Choi, Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim, Seong Hoon Yoon, Yoonjoo Kim, Jeong Eun Lee
Tuberculosis and Respiratory Diseases.2024; 87(4): 483.     CrossRef
Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer
Green Hong, Pureum Sun, Chaeuk Chung, Dongil Park, Song-I Lee, Nayoung Kim, Seong Eun Lee, Jeong Eun Lee, Yea Eun Kang, Da Hyun Kang
Journal of Cancer Research and Clinical Oncology.2023; 149(1): 159.     CrossRef
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors
Da Hyun Kang, Chaeuk Chung, Pureum Sun, Da Hye Lee, Song-I Lee, Dongil Park, Jeong Suk Koh, Yoonjoo Kim, Hyon-Seung Yi, Jeong Eun Lee
Cancer Immunology, Immunotherapy.2022; 71(3): 579.     CrossRef
The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report
Zhiru Gao, Yinghui Xu, Jianjiao Zu, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Kewei Ma
Frontiers in Immunology.2022;[Epub]     CrossRef
Recent advances in diagnostic technologies in lung cancer
Hye Jung Park, Sang Hoon Lee, Yoon Soo Chang
The Korean Journal of Internal Medicine.2020; 35(2): 257.     CrossRef
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
Da Hyun Kang, Cheol-Kyu Park, Chaeuk Chung, In-Jae Oh, Young-Chul Kim, Dongil Park, Jinhyun Kim, Gye Cheol Kwon, Insun Kwon, Pureum Sun, Eui-Cheol Shin, Jeong Eun Lee
Immune Network.2020;[Epub]     CrossRef
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Seung Eun Lee, Yu Jin Kim, Minjung Sung, Mi-Sook Lee, Joungho Han, Hong Kwan Kim, Yoon-La Choi
International Journal of Molecular Sciences.2019; 20(19): 4794.     CrossRef